McKeage, Kate; Lyseng-Williamson, Katherine A. - In: PharmacoEconomics 26 (2008) 8, pp. 699-719
Trastuzumab (Herceptin(R)) is a monoclonal antibody approved for the treatment of breast cancer that overexpresses human epidermal growth factor receptor 2 (HER2). Well designed clinical trials in women with early breast cancer have demonstrated that 1 years' therapy with adjuvant intravenous...